Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Carcinoma, Renal Cell 21Parkinson Disease 4, Autosomal Dominant Lewy Body 5Kidney Neoplasms 5von Hippel-Lindau Disease 4Pheochromocytoma 2Paraganglioma 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Metastatic Castration-Resistant Prostate Cancer 1Hemangioblastoma 1Glioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Temozolomide 101Radiotherapy 50Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 23Bevacizumab 23Lomustine 16Nivolumab 14Surgical Procedures, Operative 11atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7Carboplatin 7fludarabine 6Radiotherapy, Intensity-Modulated 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5regorafenib 4poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × belzutifan × 1 year × Clear all
NCT02974738 2025-07-10

MK-6482-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting
120 enrolled
CNSGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡